These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 15163706)

  • 1. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients.
    Hofmann H; Hattermann K; Marzi A; Gramberg T; Geier M; Krumbiegel M; Kuate S; Uberla K; Niedrig M; Pöhlmann S
    J Virol; 2004 Jun; 78(12):6134-42. PubMed ID: 15163706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein.
    Giroglou T; Cinatl J; Rabenau H; Drosten C; Schwalbe H; Doerr HW; von Laer D
    J Virol; 2004 Sep; 78(17):9007-15. PubMed ID: 15308697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.
    Temperton NJ; Chan PK; Simmons G; Zambon MC; Tedder RS; Takeuchi Y; Weiss RA
    Emerg Infect Dis; 2005 Mar; 11(3):411-6. PubMed ID: 15757556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
    Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV.
    Fukushi S; Mizutani T; Saijo M; Kurane I; Taguchi F; Tashiro M; Morikawa S
    J Med Virol; 2006 Dec; 78(12):1509-12. PubMed ID: 17063504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Potent neutralization antibody elicited in mice by SARS-associated coronavirus spike protein S1 domain].
    Zhang Y; Yang F; Li YH; Li WH; Tu XM; Wei Q; Zhu H; Liu L; Wang H; Qin C; Yuan GY; He W; Wang SH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):258-60. PubMed ID: 15640862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway.
    Jaume M; Yip MS; Cheung CY; Leung HL; Li PH; Kien F; Dutry I; Callendret B; Escriou N; Altmeyer R; Nal B; Daëron M; Bruzzone R; Peiris JS
    J Virol; 2011 Oct; 85(20):10582-97. PubMed ID: 21775467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS.
    Callendret B; Lorin V; Charneau P; Marianneau P; Contamin H; Betton JM; van der Werf S; Escriou N
    Virology; 2007 Jul; 363(2):288-302. PubMed ID: 17331558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses.
    Sampson AT; Heeney J; Cantoni D; Ferrari M; Sans MS; George C; Di Genova C; Mayora Neto M; Einhauser S; Asbach B; Wagner R; Baxendale H; Temperton N; Carnell G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development and application of a safe SARS-CoV neutralization assay based on lentiviral vectors pseudotyped with SARS-CoV spike protein].
    Yan KX; Tan WJ; Zhang XM; Wang HJ; Li Y; Ruan L
    Bing Du Xue Bao; 2007 Nov; 23(6):440-6. PubMed ID: 18092680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice.
    Yan K; Tan W; Wang H; Wang Y; Zhang X; Li Y; Ruan L
    Viral Immunol; 2009 Feb; 22(1):57-66. PubMed ID: 19210229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.
    Liu RY; Wu LZ; Huang BJ; Huang JL; Zhang YL; Ke ML; Wang JM; Tan WP; Zhang RH; Chen HK; Zeng YX; Huang W
    Virus Res; 2005 Sep; 112(1-2):24-31. PubMed ID: 16022898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
    Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
    Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response.
    Glowacka I; Bertram S; Müller MA; Allen P; Soilleux E; Pfefferle S; Steffen I; Tsegaye TS; He Y; Gnirss K; Niemeyer D; Schneider H; Drosten C; Pöhlmann S
    J Virol; 2011 May; 85(9):4122-34. PubMed ID: 21325420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
    Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
    J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein.
    Han DP; Kim HG; Kim YB; Poon LL; Cho MW
    Virology; 2004 Aug; 326(1):140-9. PubMed ID: 15262502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.